Vicore Pharma Holding Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Ahmed Mousa

Algemeen directeur

SEK 6.3m

Totale compensatie

Percentage CEO-salaris	23.5%
Dienstverband CEO	1.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	1.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ahmed Mousa's beloning veranderd ten opzichte van Vicore Pharma Holding's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-SEK 196m
Jun 30 2024	n/a	n/a	-SEK 200m
Mar 31 2024	n/a	n/a	-SEK 213m
Dec 31 2023	SEK 6m	SEK 1m	-SEK 311m

Compensatie versus markt: De totale vergoeding ($USD 593.12K ) Ahmed } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 808.68K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Ahmed te vergelijken met de prestaties van het bedrijf.

CEO

Ahmed Mousa (39 yo)

1.8yrs

Tenure

SEK 6,339,074

Compensatie

Mr. Ahmed S. Mousa, J. D., serves as Chief Executive Officer at Vicore Pharma Holding AB (publ) since 2023. He served as General Counsel at Pieris Pharmaceuticals, Inc., since October 2018 until September...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ahmed Mousa	Chief Executive Officer	1.8yrs	SEK 6.34m	geen gegevens
Hans Jeppsson	Chief Financial Officer	7.4yrs	geen gegevens	0.0021% € 3.5k
Mikael Nygård	Vice President of Operations & Corporate Strategy	less than a year	geen gegevens	0.0017% € 2.8k
Johan Raud	Chief Scientific Officer	6.8yrs	geen gegevens	0.10% € 168.8k
Nina Carlen	Chief Administrative Officer	15.8yrs	geen gegevens	0.010% € 17.3k
Megan Richards	VP of Investor Relations	less than a year	geen gegevens	geen gegevens
Jessica Shull	Head of Digital Therapeutics & Director of Digital Innovation	3.5yrs	geen gegevens	geen gegevens
Asa Magnusson	Chief Engagement & Commercial Officer	3.1yrs	geen gegevens	geen gegevens
Bertil Lindmark	Chief Medical Officer	less than a year	geen gegevens	geen gegevens
Jimmie Hofman	Vice President of Business Development	less than a year	geen gegevens	geen gegevens
Helen Barker	VP & Head of CMC	less than a year	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 6Y4 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jacob Gunterberg	Independent Director	no data	SEK 886.00k	0.0027% € 4.5k
Michael Buschle	Director	1.5yrs	SEK 405.00k	geen gegevens
Ann Barbier	Independent Director	less than a year	geen gegevens	geen gegevens
Yasir Al-Wakeel	Independent Director	less than a year	geen gegevens	geen gegevens
Hans J. G. C. Schikan	Independent Chairman	6.3yrs	SEK 450.00k	0.0017% € 2.8k
Elisabeth Bjork	Director	1.5yrs	SEK 405.00k	geen gegevens
Heidi Hunter	Independent Director	4.5yrs	SEK 519.00k	0.0021% € 3.5k

1.5yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6Y4 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw bestuur.

Vicore Pharma Holding Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Vicore Pharma Holding AB (publ), Annual General Meeting, May 06, 2025

Less than half of directors are independent

Vicore Pharma Holding AB (Publ) Announces Board Appointments

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Recent updates

Vicore Pharma Holding AB (publ) to Report Q2, 2025 Results on Aug 22, 2025

Vicore Pharma Holding AB (publ), Annual General Meeting, May 06, 2025

New major risk - Shareholder dilution

Vicore Pharma Holding AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 782.138028 million.

Vicore Pharma Holding AB Initiates the Global, Randomized Phase 2B Aspre Trial Evaluating the Disease-Modifying Potential of Buloxibutid in Idiopathic Pulmonary Fibrosis

Less than half of directors are independent

Vicore Pharma Holding AB (Publ) Announces Board Appointments

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

No longer forecast to breakeven

Vicore Pharma Holding AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

New minor risk - Share price stability

Vicore Pharma Holding AB (publ) Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

New minor risk - Share price stability

Vicore Pharma Holding AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Vicore Pharma Holding AB (publ) Provides Update Regarding Phase 1 Study of C106

New major risk - Revenue and earnings growth

Vicore Pharma Holding AB (publ) Reports Data from EndoPAT® Exploratory Trial

New major risk - Shareholder dilution

Vicore Pharma Holding AB (Publ) Announces Executive Changes

Vicore Pharma Holding AB (publ) Reports New 36-Week Data from the Air Trial Demonstrating Sustainable Disease Stimulating the Potential of A New Class of Drugs to Stop Disease Propose and Restate in IPF Patients

Vicore Pharma Holding AB (publ) to Report Q2, 2023 Results on Aug 24, 2023

Vicore Pharma Holding AB (publ) Announces First Patient Enrolled in COMPANION; a Digital Therapeutic Pivotal Study for Patients with Pulmonary Fibrosis

Vicore Pharma Holding AB (publ) Announces New Data from the IPF Air Trial Further Strengthening the Benefit-Risk Profile of C21

Vicore Pharma Holding AB (publ) Announces the Appointment of Nomination Committee

Vicore Selects New ATRAG as Next Drug Candidate

Vicore Pharma Holding AB (publ) Announces Positive Results for the Pilot Phase of the COMPANION study

Vicore Pharma Holding AB Announces C21 Promotes Vascular Function in Humans

Vicore Pharma Holding AB (Publ) Provides an Update on the Attract-3 Covid-19 Trial

Vicore Pharma Holding AB (publ) Announces Initiation of First-In-Human Trial with the Novel ATRAG C106

Vicore Pharma Holding AB (publ) Amends Primary Endpoint to Accelerate the Phase 3 Trial in COVID-19 Patients

Vicore Launches COMPANION, A Clinical Study Investigating the Benefit of Digital Therapy on Anxiety in Patients with Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (Publ) Announces Plans to Initiate A Clinical Trial with C21 in PAH

Vicore Pharma Holding AB (Publ) Announces Advancing its First New Chemical Entity from the VP03 Program to a First in Human Phase 1 Trial

Vicore Pharma Holding Announces Data from an Interim Analysis of the Phase 2 Proof-of-Concept Study in IPF

Vicore Pharma Holding AB (publ) Starts Dosing of First Covid-19 Patients in the Global Phase 3 Trial ATTRACT-3

No longer forecast to breakeven

High number of new directors

Vicore Pharma Holding AB (publ) Announces FDA Acceptance for Pivotal Phase 3 Trial of C21 in COVID-19

Vicore Pharma Holding AB (Publ) Announces Top Line Data from A Phase Ii Study of Its Oral Angiotensin II Type 2 Receptor (AT2R) Agonist C21 in Patients with Systemic Sclerosis and Raynaud's Phenomenon

Vicore Pharma Holding AB (Publ) Resumes VP02 Production

Vicore Pharma Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 336 million.

Vicore Pharma Holding AB Announces Positive Data from Phase II Study Attract in Patients with Covid-19 Published Online

New 90-day high: €2.82

Vicore Pharma Holding Reports an Expanded Data Analysis to Follow Up the Encouraging Top Line Data from the ATTRACT

Vicore Pharma Holding AB (Publ) Announces Last Patient Last Visit in the Mechanistic Phase II Study with C21 in Systemic Sclerosis

Vicore Pharma Reports Positive Top Line Data from the ATTRACT clinical study in patients with COVID-19

New 90-day low: €1.78

Vicore Pharma Holding AB Recruits the First Patient in the Phase II Proof-Of-Concept Study in Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (publ) to Report Fiscal Year 2020 Final Results on Apr 15, 2021

Vicore Pharma Holding AB (publ) to Report Q2, 2021 Results on Aug 26, 2021

Vicore Pharma Holding AB (Publ) Announces Completion of Patient Enrollment in the Covid-19 Attract Trial

Vicore Pharma Holding AB (publ) Announces Robust Effects of VP01 in Human Idiopathic Pulmonary Fibrosis Lung Tissue

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd